Harry Karelis
Follow
Get notifications in MyBN when activity occurs.
Harry Karelis
Harry Karelis is the founder of Titan Capital Partners - a privately held investment group involved in a range of projects.
Mr Karelis has over 23 years of diversified experience in the financial services sector including fundamental analysis, funds management and private equity investing. He has considerable cross-border experience and has acted as a Director on several public and private companies in Australia, Singapore, the United Kingdom and America.
Mr Karelis graduated from The University of Western Australia with Bachelors and Honours in Science majoring in Biochemistry and Microbiology as well as a Masters in Business Administration. He is a Fellow of the Financial Services Institute of Australia, a Fellow of the Australian Institute of Company Directors and has qualified as a Chartered Financial Analyst (CFA) from the CFA Institute in the United States.
Mr Karelis has over 23 years of diversified experience in the financial services sector including fundamental analysis, funds management and private equity investing. He has considerable cross-border experience and has acted as a Director on several public and private companies in Australia, Singapore, the United Kingdom and America.
Mr Karelis graduated from The University of Western Australia with Bachelors and Honours in Science majoring in Biochemistry and Microbiology as well as a Masters in Business Administration. He is a Fellow of the Financial Services Institute of Australia, a Fellow of the Australian Institute of Company Directors and has qualified as a Chartered Financial Analyst (CFA) from the CFA Institute in the United States.
Lists and Charts
Total Shareholder Return as at 28/06/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 100th | PYC Therapeutics | 117% | 34% |
| 888th | Alexium International Group | -7% | -38% |
| 1139th | DTI Group | -27% | -17% |
| 1467th | RooLife Group | -50% |
1769 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 87th |  | PYC Therapeutics | $15.8m |
| 94th |  | DTI Group | $13.3m |
| 95th | | RooLife Group | $12.7m |
| 97th | | Ozgrowth | $12.2m |
| 98th | | Alexium International Group | $12.1m |
202 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEWS: Tagged in Sapien Cyber to be wound up | 16 Apr 2024 |
| NEWS: Tagged in Sapien Cyber into administration | 01 Mar 2024 |
News Articles
Related Information
Positions - Previous
| Position | Company | Year | Company's current rank |
|---|---|---|---|
| Non-Executive Director | | 2016 - 2023 | |
| Non-Executive Deputy Chair | | 2019 - 2022 | 155 |
| Non-Executive Chair | | 2019 - 2019 | 155 |
| Co-Founder, Executive Chair | | 2015 - 2019 | 155 |
| Non-Executive Director | | 2014 - 2018 | |
| Executive Director | | 2014 - 2017 | 154 |
| Non-Executive Director | | 2014 - 2016 | |
| Managing Director | | - 2014 | 1268 |
| Non-Executive Director | | 2005 - 2011 | 87 |
| Non-Executive Chair | | - 2011 | 970 |
| Co-Founder, Director | | 2015 - | |
| Non-Executive Director | | - | |
| Non-Executive Director | | - | 172 |
| Non-Executive Director | | - | |
| Non-Executive Director | | - |
Directors Interests
| Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
|---|---|---|---|---|---|---|
| Zelira Therapeutics | 03 Feb 2022 | Bought | 6,250,000 | $0.03 | $175,000 | OtherConversion of securities |
| Zelira Therapeutics | 03 Feb 2022 | Other | 6,250,000 | $0.03 | $175,000 | OtherConversion of securities: 6,250,000 performance rights |
| Zelira Therapeutics | 17 Nov 2021 | Other | 6,000,000 | OtherOptions expired | ||
| Zelira Therapeutics | 23 Dec 2019 | Issued | 12,500,000 | $0.00 | $1,250 | OtherIssue of securities: 12,500,000 - performance rights. |
| AusCann Group Holdings | 10 May 2017 | Other | 2,545,062 | OtherConversion of securities |
Powered by Morningstar ®
Equity Capital Markets Deals
| Date | Company | Transaction Type | Total Value | |
|---|---|---|---|---|
| 30/03/17 | Zelira Therapeutics | Placement | $6.0m | >> |
| 30/05/16 | Gleneagle Gold | Convertible notes | $1.1m | >> |
| 15/08/17 | Clinicann | Placement | $1.1m | >> |
